820 results on '"Mcguire, P. K."'
Search Results
2. Human milk oligosaccharides are associated with maternal genetics and respiratory health of human milk-fed children
- Author
-
Ambalavanan, Amirthagowri, Chang, Le, Choi, Jihoon, Zhang, Yang, Stickley, Sara A., Fang, Zhi Y., Miliku, Kozeta, Robertson, Bianca, Yonemitsu, Chloe, Turvey, Stuart E., Mandhane, Piushkumar J., Simons, Elinor, Moraes, Theo J., Anand, Sonia S., Paré, Guillaume, Williams, Janet E., Murdoch, Brenda M., Otoo, Gloria E., Mbugua, Samwel, Kamau-Mbuthia, Elizabeth W., Kamundia, Egidioh W., Gindola, Debela K., Rodriguez, Juan M., Pareja, Rossina G., Sellen, Daniel W., Moore, Sophie E., Prentice, Andrew M., Foster, James A., Kvist, Linda J., Neibergs, Holly L., McGuire, Mark A., McGuire, Michelle K., Meehan, Courtney L., Sears, Malcolm R., Subbarao, Padmaja, Azad, Meghan B., Bode, Lars, and Duan, Qingling
- Published
- 2024
- Full Text
- View/download PDF
3. Cannabis use, decision making, and perceptions of risk among breastfeeding individuals: the Lactation and Cannabis (LAC) Study
- Author
-
Smith, Caroline B., Schmidt, Jenna, Holdsworth, Elizabeth A., Caffé, Beatrice, Brooks, Olivia, Williams, Janet E., Gang, David R., McGuire, Mark A., McGuire, Michelle K., Barbosa-Leiker, Celestina, and Meehan, Courtney L.
- Published
- 2024
- Full Text
- View/download PDF
4. Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions
- Author
-
Harrington, Josephine, Felker, G. Michael, Januzzi, James L., Lam, Carolyn S. P., Lingvay, Ildiko, Pagidipati, Neha J., Sattar, Naveed, Van Spall, Harriette G. C., Verma, Subodh, and McGuire, Darren K.
- Published
- 2024
- Full Text
- View/download PDF
5. Ecologies, synergies, and biological systems shaping human milk composition—a report from “Breastmilk Ecology: Genesis of Infant Nutrition (BEGIN)” Working Group 2
- Author
-
Smilowitz, Jennifer T, Allen, Lindsay H, Dallas, David C, McManaman, James, Raiten, Daniel J, Rozga, Mary, Sela, David A, Seppo, Antti, Williams, Janet E, Young, Bridget E, and McGuire, Michelle K
- Subjects
Biomedical and Clinical Sciences ,Nutrition and Dietetics ,Clinical Sciences ,Infant Mortality ,Nutrition ,Pediatric ,Female ,Infant ,Humans ,Milk ,Human ,Breast Feeding ,Infant Nutritional Physiological Phenomena ,human milk ,breast milk ,composition ,ecology ,systems biology ,nutrition ,Engineering ,Medical and Health Sciences ,Nutrition & Dietetics ,Clinical sciences ,Nutrition and dietetics - Abstract
Human milk is universally recognized as the preferred food for infants during the first 6 mo of life because it provides not only essential and conditionally essential nutrients in necessary amounts but also other biologically active components that are instrumental in protecting, communicating important information to support, and promoting optimal development and growth in infants. Despite decades of research, however, the multifaceted impacts of human milk consumption on infant health are far from understood on a biological or physiological basis. Reasons for this lack of comprehensive knowledge of human milk functions are numerous, including the fact that milk components tend to be studied in isolation, although there is reason to believe that they interact. In addition, milk composition can vary greatly within an individual as well as within and among populations. The objective of this working group within the Breastmilk Ecology: Genesis of Infant Nutrition (BEGIN) Project was to provide an overview of human milk composition, factors impacting its variation, and how its components may function to coordinately nourish, protect, and communicate complex information to the recipient infant. Moreover, we discuss the ways whereby milk components might interact such that the benefits of an intact milk matrix are greater than the sum of its parts. We then apply several examples to illustrate how milk is better thought of as a biological system rather than a more simplistic "mixture" of independent components to synergistically support optimal infant health.
- Published
- 2023
6. The need for increased pragmatism in cardiovascular clinical trials
- Author
-
Usman, Muhammad Shariq, Van Spall, Harriette GC, Greene, Stephen J, Pandey, Ambarish, McGuire, Darren K, Ali, Ziad A, Mentz, Robert J, Fonarow, Gregg C, Spertus, John A, Anker, Stefan D, Butler, Javed, James, Stefan K, and Khan, Muhammad Shahzeb
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Comparative Effectiveness Research ,Cardiovascular ,Heart Disease ,Clinical Trials and Supportive Activities ,Prevention ,Clinical Research ,Good Health and Well Being ,Cardiovascular Diseases ,Humans ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
The majority of cardiovascular randomized controlled trials (RCTs) test interventions in selected patient populations under explicitly protocol-defined settings. Although these 'explanatory' trial designs optimize conditions to test the efficacy and safety of an intervention, they limit the generalizability of trial findings in broader clinical settings. The concept of 'pragmatism' in RCTs addresses this concern by providing counterbalance to the more idealized situation underpinning explanatory RCTs and optimizing effectiveness over efficacy. The central tenets of pragmatism in RCTs are to test interventions in routine clinical settings, with patients who are representative of broad clinical practice, and to reduce the burden on investigators and participants by minimizing the number of trial visits and the intensity of trial-based testing. Pragmatic evaluation of interventions is particularly important in cardiovascular diseases, where the risk of death among patients has remained fairly stable over the past few decades despite the development of new therapeutic interventions. Pragmatic RCTs can help to reveal the 'real-world' effectiveness of therapeutic interventions and elucidate barriers to their implementation. In this Review, we discuss the attributes of pragmatism in RCT design, conduct and interpretation as well as the general need for increased pragmatism in cardiovascular RCTs. We also summarize current challenges and potential solutions to the implementation of pragmatism in RCTs and highlight selected ongoing and completed cardiovascular RCTs with pragmatic trial designs.
- Published
- 2022
7. The relationship between striatal dopamine and anterior cingulate glutamate in first episode psychosis changes with antipsychotic treatment
- Author
-
Jauhar, Sameer, McCutcheon, Robert A., Veronese, Mattia, Borgan, Faith, Nour, Matthew, Rogdaki, Maria, Pepper, Fiona, Stone, James M., Egerton, Alice, Vamvakas, George, Turkheimer, Federico, McGuire, Philip K., and Howes, Oliver D.
- Published
- 2023
- Full Text
- View/download PDF
8. Cardiac arrhythmias and conduction abnormalities in patients with type 2 diabetes
- Author
-
Rawshani, Araz, McGuire, Darren K., Omerovic, Elmir, Sattar, Naveed, McMurray, John J. V., Smith, Ulf, Redfors, Bjorn, Bergfeldt, Lennart, Eliasson, Bjorn, Borén, Jan, Bhatt, Deepak L., Bergstrom, Goran, and Rawshani, Aidin
- Published
- 2023
- Full Text
- View/download PDF
9. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
- Author
-
McCutcheon, Robert A., Keefe, Richard S. E., and McGuire, Philip K.
- Published
- 2023
- Full Text
- View/download PDF
10. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
- Author
-
Wojeck, Brian S., Inzucchi, Silvio E., Neeland, Ian J., Mancuso, James P., Frederich, Robert, Masiukiewicz, Urszula, Cater, Nilo B., McGuire, Darren K., Cannon, Christopher P., and Yaggi, Henry Klar
- Published
- 2023
- Full Text
- View/download PDF
11. In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction
- Author
-
Rao, Vishal N, Murray, Evan, Butler, Javed, Cooper, Lauren B, Cox, Zachary L, Fiuzat, Mona, Green, Jennifer B, Lindenfeld, JoAnn, McGuire, Darren K, Nassif, Michael E, O'Brien, Cara, Pagidipati, Neha, Sharma, Kavita, Vaduganathan, Muthiah, Vardeny, Orly, Fonarow, Gregg C, Mentz, Robert J, and Greene, Stephen J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Cardiovascular ,Heart Disease ,Clinical Research ,Patient Safety ,5.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Development of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Diabetes Mellitus ,Type 2 ,Heart Failure ,Hospitalization ,Humans ,Hypoglycemic Agents ,Patient Discharge ,Patient Readmission ,Patient-Centered Care ,Practice Guidelines as Topic ,Randomized Controlled Trials as Topic ,Risk ,Sodium-Glucose Transporter 2 ,Sodium-Glucose Transporter 2 Inhibitors ,Stroke Volume ,Ventricular Dysfunction ,Left ,  ,guideline-directed medical therapy ,heart failure ,in-hospital prescribing ,medical therapy ,sodium-glucose cotransporter-2 inhibitors ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effects on blood pressure, and no excess risk of adverse kidney events. There is no evidence to suggest that deferring initiation to the outpatient setting accomplishes anything beneficial. Instead, there is compelling evidence that deferring in-hospital initiation exposes patients to excess risk of early postdischarge clinical worsening and death. Lessons from other heart failure with reduced ejection fraction therapies highlight that deferring initiation of guideline-recommended medications to the U.S. outpatient setting carries a >75% chance they will not be initiated within the next year. Recognizing that 1 in 4 patients hospitalized for worsening heart failure die or are readmitted within 30 days, clinicians should embrace the in-hospital period as an optimal time to initiate sodium-glucose cotransporter-2 inhibitor therapy and treat this population with the urgency it deserves.
- Published
- 2021
12. Global research priorities on COVID-19 for maternal, newborn, child and adolescent health
- Author
-
ASM, Nawshad Uddin Ahmed, Maamri, Abdellatif, Falade, Adegoke G, Ayede, Adejumoke Idowu, Bhutta, Adnan, Gambhir, Ajay, Tagarro, Alfredo, Abdelmegeid, Ali, Ahmadi, Ali Reza, Barros, Aluísio JD, Mekasha, Amha, Srinivasaiyer, Anantha Kumar, da Silva, André Ricardo Araujo, Schultz, Andreas, Fatima, Batool, Dhar, Bishnupada, Magowan, Brian, Wills, Bridget, Raynes-Greenow, Camille, Homer, Caroline, Maclennan, Carolyn, Ward, Catherine, Garcia, Daniel Martinez, Ross, David, Murdoch, David, Wilson, Deborah Joy, Adejuyigbe, Ebun, Stasii, Ecaterina, Scudder, Elaine, Sacks, Emma, McCollum, Eric D, Althabe, Fernando, Russell, Fiona, Kumar, GS, Sommerfelt, Halvor, Graham, Hamish, Blencowe, Hannah, Tappis, Hannah, Saloojee, Haroon, Masaud, Hesham Abdussalam Ben, Tiwary, Hiresh, Asiodu, Ifeyinwa, Newton, James B, Bourdaire, Jessica, Adze, Joel Amwe, Martines, Jose, Lozano, Juan M, Walson, Judd, Rankin, Judith, Allegaert, Karel, Pellé, Karell G, Edmond, Karen, Rabiei, Katayoun, Rasmussen, Kathleen M, Yunis, Khalid, Ferguson, Laura, Greenslade, Leith, Kiapi, Lilian, Noguchi, Lisa, Bont, Louis, Day, Louise T, Mofenson, Lynne, Aboumayaleh, Maher, Aquzouz, Majda, Wahba, Mamdouh, Nagai, Mari, Knight, Marian, Melkumova, Marina, Jenyfa, Mariyam, Neuman, Mark I, Meremikwu, Martin, Kinney, Mary, Gravett, Michael, Hawkes, Michael T, Pacqué, Michel, Walsh, Michele, McGuire, Michelle K, AlShawafi, Nagiba AAbdulghani, Khuri-Bulos, Najwa, Thacker, Naveen, Rollins, Nigel, Kissoon, Niranjan, Starets, Olena, Picone, Olivier, Oladapo, Olufemi T, Erdeve, Omer, Smith, P Brian, Van de Perre, Philippe, Kumar, Praveen, Mangtani, Punam, Abbas, Qalab, Khatoon, Rabeya, Bahl, Rajiv, Lodha, Rakesh, Grais, Rebecca, Richards-Kortum, Rebecca, Rasaily, Reeta, Aryeetey, Richmond, Pattinson, Robert, and Petrucci, Roberta
- Subjects
Public Health ,Health Sciences ,Pediatric ,Prevention ,Perinatal Period - Conditions Originating in Perinatal Period ,Good Health and Well Being ,Adolescent ,Adolescent Health ,COVID-19 ,Child ,Child Health ,Female ,Global Health ,Humans ,Infant ,Newborn ,Pandemics ,Research ,SARS-CoV-2 ,COVID-19 Research Prioritization Group on MNCAH ,Public Health and Health Services ,Public health - Abstract
BackgroundThis research prioritization aimed to identify major research gaps in maternal, newborn, child and adolescent health (MNCAH) to help mitigate the direct and indirect effects of the COVID-19 pandemic.MethodsWe adapted the Child Health and Nutrition Research Initiative methodology. We defined scope, domains, themes and scoring criteria. We approached diverse global experts via email to submit their research ideas in MNCAH and MNCAH-related cross-cutting/health systems area. We curated the research ideas as research questions (RQs) and sent them to the consenting experts for scoring via the online link. For each RQ, the research priority score (RPS) was calculated as an average of individual criterion scores and ranked based on RPS in each area.ResultsWe identified top-ranked 10 RQs in each maternal, newborn, and child and adolescent health and 5 in the cross-cutting/health systems area. In maternal health, indirect effects on care, measures to improve care, health risks and outcomes, and preventing and managing SARS-CoV-2 infection/COVID-19 disease were priority RQs. In newborn health, clinical characterization and managing SARS-CoV-2 infection/COVID-19 disease, mode of transmission and interventions to prevent transmission were the focus. For child and adolescent health, top-ranked RQs were indirect effects on care, clinical status and outcomes, interventions to protect against SARS-CoV-2 infection/COVID-19 disease, and educational institute-related RQs. The cross-cutting RQs were the effects of the pandemic on availability, access, care-seeking and utilization of MNCAH services and potential solutions.ConclusionsWe call on partners, including governments, non-governmental organizations, research institutes, and donors, to address this urgent research agenda.
- Published
- 2021
13. Medicaid Expansion and Utilization of Antihyperglycemic Therapies
- Author
-
Sumarsono, Andrew, Buckley, Leo F, Machado, Sara R, Wadhera, Rishi K, Warraich, Haider J, Desai, Rishi J, Everett, Brendan M, McGuire, Darren K, Fonarow, Gregg C, Butler, Javed, Pandey, Ambarish, and Vaduganathan, Muthiah
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Health Services ,Clinical Research ,Good Health and Well Being ,Adult ,Diabetes Mellitus ,Type 2 ,Drug Utilization ,Female ,Glucagon-Like Peptide-1 Receptor ,Humans ,Male ,Medicaid ,Patient Protection and Affordable Care Act ,Poverty ,Sodium-Glucose Transporter 2 Inhibitors ,United States ,Medical and Health Sciences ,Endocrinology & Metabolism ,Biomedical and clinical sciences ,Health sciences - Abstract
ObjectiveCertain antihyperglycemic therapies modify cardiovascular and kidney outcomes among patients with type 2 diabetes, but early uptake in practice appears restricted to particular demographics. We examine the association of Medicaid expansion with use of and expenditures related to antihyperglycemic therapies among Medicaid beneficiaries.Research design and methodsWe employed a difference-in-difference design to analyze the association of Medicaid expansion on prescription of noninsulin antihyperglycemic therapies. We used 2012-2017 national and state Medicaid data to compare prescription claims and costs between states that did (n = 25) and did not expand (n = 26) Medicaid by January 2014.ResultsFollowing Medicaid expansion in 2014, average noninsulin antihyperglycemic therapies per state/1,000 enrollees increased by 4.2%/quarter in expansion states and 1.6%/quarter in nonexpansion states. For sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA), quarterly growth rates per 1,000 enrollees were 125.3% and 20.7% for expansion states and 87.6% and 16.0% for nonexpansion states, respectively. Expansion states had faster utilization of SGLT2i and GLP-1RA than nonexpansion states. Difference-in-difference estimates for change in volume of prescriptions after Medicaid expansion between expansion versus nonexpansion states was 1.68 (95% CI 1.09-2.26; P < 0.001) for all noninsulin therapies, 0.125 (-0.003 to 0.25; P = 0.056) for SGLT2i, and 0.12 (0.055-0.18; P < 0.001) for GLP-1RA.ConclusionsUse of noninsulin antihyperglycemic therapies, including SGLT2i and GLP-1RA, increased among low-income adults in both Medicaid expansion and nonexpansion states, with a significantly greater increase in overall use and in GLP-1RA use in expansion states. Future evaluation of the population-level health impact of expanded access to these therapies is needed.
- Published
- 2020
14. Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial
- Author
-
Segar, Matthew W, Patel, Kershaw V, Vaduganathan, Muthiah, Caughey, Melissa C, Butler, Javed, Fonarow, Gregg C, Grodin, Justin L, McGuire, Darren K, and Pandey, Ambarish
- Subjects
Heart Disease ,Prevention ,Diabetes ,Clinical Research ,Cardiovascular ,Metabolic and endocrine ,Aged ,Blood Glucose ,Diabetes Mellitus ,Type 2 ,Diabetic Angiopathies ,Female ,Follow-Up Studies ,Glycated Hemoglobin ,Glycemic Control ,Heart Failure ,Humans ,Incidence ,Male ,Middle Aged ,Retrospective Studies ,Risk Factors ,Time Factors - Abstract
ObjectiveTo evaluate the associations between long-term change and variability in glycemia with risk of heart failure (HF) among patients with type 2 diabetes mellitus (T2DM).Research design and methodsAmong participants with T2DM enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, variability in HbA1c was assessed from stabilization of HbA1c following enrollment (8 months) to 3 years of follow-up as follows: average successive variability (ASV) (average absolute difference between successive values), coefficient of variation (SD/mean), and SD. Participants with HF at baseline or within 3 years of enrollment were excluded. Adjusted Cox models were used to evaluate the association of percent change (from baseline to 3 years of follow-up) and variability in HbA1c over the first 3 years of enrollment and subsequent risk of HF.ResultsThe study included 8,576 patients. Over a median follow-up of 6.4 years from the end of variability measurements at year 3, 388 patients had an incident HF hospitalization. Substantial changes in HbA1c were significantly associated with higher risk of HF (hazard ratio [HR] for ≥10% decrease 1.32 [95% CI 1.08-1.75] and for ≥10% increase 1.55 [1.19-2.04]; reference
- Published
- 2020
15. Effect on Patient Safety of a Resident Physician Schedule without 24-Hour Shifts
- Author
-
Landrigan, Christopher P, Rahman, Shadab A, Sullivan, Jason P, Vittinghoff, Eric, Barger, Laura K, Sanderson, Amy L, Wright, Kenneth P, O'Brien, Conor S, Qadri, Salim, St Hilaire, Melissa A, Halbower, Ann C, Segar, Jeffrey L, McGuire, John K, Vitiello, Michael V, de la Iglesia, Horacio O, Poynter, Sue E, Yu, Pearl L, Zee, Phyllis C, Lockley, Steven W, Stone, Katie L, and Czeisler, Charles A
- Subjects
Clinical Trials and Supportive Activities ,Patient Safety ,Clinical Research ,Prevention ,Cross-Over Studies ,Humans ,Intensive Care Units ,Pediatric ,Internship and Residency ,Medical Errors ,Personnel Staffing and Scheduling ,Psychomotor Performance ,Sleep ,Time Factors ,Work Schedule Tolerance ,Workload ,ROSTERS Study Group ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundThe effects on patient safety of eliminating extended-duration work shifts for resident physicians remain controversial.MethodsWe conducted a multicenter, cluster-randomized, crossover trial comparing two schedules for pediatric resident physicians during their intensive care unit (ICU) rotations: extended-duration work schedules that included shifts of 24 hours or more (control schedules) and schedules that eliminated extended shifts and cycled resident physicians through day and night shifts of 16 hours or less (intervention schedules). The primary outcome was serious medical errors made by resident physicians, assessed by intensive surveillance, including direct observation and chart review.ResultsThe characteristics of ICU patients during the two work schedules were similar, but resident physician workload, described as the mean (±SD) number of ICU patients per resident physician, was higher during the intervention schedules than during the control schedules (8.8±2.8 vs. 6.7±2.2). Resident physicians made more serious errors during the intervention schedules than during the control schedules (97.1 vs. 79.0 per 1000 patient-days; relative risk, 1.53; 95% confidence interval [CI], 1.37 to 1.72; P
- Published
- 2020
16. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus
- Author
-
Butler, Javed, Packer, Milton, Greene, Stephen J, Fiuzat, Mona, Anker, Stefan D, Anstrom, Kevin J, Carson, Peter E, Cooper, Lauren B, Fonarow, Gregg C, Hernandez, Adrian F, Januzzi, James L, Jessup, Mariell, Kalyani, Rita R, Kaul, Sanjay, Kosiborod, Mikhail, Lindenfeld, JoAnn, McGuire, Darren K, Sabatine, Marc S, Solomon, Scott D, Teerlink, John R, Vaduganathan, Muthiah, Yancy, Clyde W, Stockbridge, Norman, and O'Connor, Christopher M
- Subjects
Cardiovascular ,Clinical Trials and Supportive Activities ,Clinical Research ,Heart Disease ,Heart Disease - Coronary Heart Disease ,Diabetes ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Cardiovascular Diseases ,Clinical Trials as Topic ,Diabetes Mellitus ,Type 2 ,Endpoint Determination ,Heart Failure ,Humans ,Research Report ,Sodium-Glucose Transporter 2 ,Sodium-Glucose Transporter 2 Inhibitors ,Treatment Outcome ,biomarkers ,clinical trial ,diabetes mellitus ,type 2 ,heart failure ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Public Health and Health Services ,Cardiovascular System & Hematology - Abstract
Following regulatory guidance set forth in 2008 by the US Food and Drug Administration for new drugs for type 2 diabetes mellitus, many large randomized, controlled trials have been conducted with the primary goal of assessing the safety of antihyperglycemic medications on the primary end point of major adverse cardiovascular events, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Heart failure (HF) was not specifically mentioned in the US Food and Drug Administration guidance and therefore it was not a focus of these studies when planned. Several trials subsequently showed the impact of antihyperglycemic drugs on HF outcomes, which were not originally specified as the primary end point of the trials. The most impressive finding has been the substantial and consistent risk reduction in HF hospitalization seen across 4 trials of sodium glucose cotransporter 2 inhibitors. However, to date, these results have not led to regulatory approval of any of these drugs for a HF indication or a recommendation for use by US HF guidelines. It is therefore important to explore to what extent persuasive treatment effects on nonprimary end points can be used to support regulatory claims and guideline recommendations. This topic was discussed by researchers, clinicians, industry sponsors, regulators, and representatives from professional societies, who convened on the US Food and Drug Administration campus on March 6, 2019. This report summarizes these discussions and the key takeaway messages from this meeting.
- Published
- 2019
17. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score
- Author
-
Segar, Matthew W, Vaduganathan, Muthiah, Patel, Kershaw V, McGuire, Darren K, Butler, Javed, Fonarow, Gregg C, Basit, Mujeeb, Kannan, Vaishnavi, Grodin, Justin L, Everett, Brendan, Willett, Duwayne, Berry, Jarett, and Pandey, Ambarish
- Subjects
Heart Disease ,Patient Safety ,Nutrition ,Prevention ,Cardiovascular ,Clinical Research ,Diabetes ,Metabolic and endocrine ,Aged ,Clinical Trials as Topic ,Cohort Studies ,Diabetes Mellitus ,Type 2 ,Female ,Follow-Up Studies ,Heart Failure ,Hospitalization ,Humans ,Incidence ,Machine Learning ,Male ,Middle Aged ,Outpatients ,Predictive Value of Tests ,Reproducibility of Results ,Risk Assessment ,Risk Factors ,Time Factors - Abstract
ObjectiveTo develop and validate a novel, machine learning-derived model to predict the risk of heart failure (HF) among patients with type 2 diabetes mellitus (T2DM).Research design and methodsUsing data from 8,756 patients free at baseline of HF, with
- Published
- 2019
18. Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
- Author
-
Salah, Husam M., Verma, Subodh, Santos-Gallego, Carlos G., Bhatt, Ankeet S., Vaduganathan, Muthiah, Khan, Muhammad Shahzeb, Lopes, Renato D., Al’Aref, Subhi J., McGuire, Darren K., and Fudim, Marat
- Published
- 2022
- Full Text
- View/download PDF
19. Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]
- Author
-
Cherney, David Z. I., Charbonnel, Bernard, Cosentino, Francesco, Dagogo-Jack, Samuel, McGuire, Darren K., Pratley, Richard, Shih, Weichung J., Frederich, Robert, Maldonado, Mario, Pong, Annpey, and Cannon, Christopher P.
- Published
- 2022
- Full Text
- View/download PDF
20. Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR)
- Author
-
Arnold, Suzanne V, McGuire, Darren K, Inzucchi, Silvio E, Tang, Fengming, Mehta, Sanjeev N, Lam, Carolyn SP, Goyal, Abhinav, Sperling, Laurence S, Wong, Nathan D, Hammar, Niklas, Fenici, Peter, and Kosiborod, Mikhail
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Cardiovascular ,Clinical Research ,Diabetes ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Metabolic and endocrine ,Good Health and Well Being ,Aged ,Aged ,80 and over ,Cohort Studies ,Cooperative Behavior ,Diabetes Mellitus ,Type 2 ,Drug Utilization ,Female ,Humans ,Hypoglycemic Agents ,Male ,Middle Aged ,Practice Patterns ,Physicians' ,Precision Medicine ,Quality Improvement ,Registries ,United States ,Diabetes mellitus ,Medications ,Patient safety ,Personalized medicine ,Endocrinology & Metabolism ,Clinical sciences - Abstract
BackgroundAlthough practice guidelines stress individualization of glucose management in patients with type 2 diabetes (T2D), the extent to which providers take patient factors into account when selecting medications is not well known.MethodsDiabetes Collaborative Registry (DCR) is an outpatient diabetes registry including primary care, cardiology, and endocrinology practices. T2D medications were grouped as those which may be suboptimal for key patient subgroups, and we examined patient factors associated with use of these agents using hierarchical, multivariable Poisson models.ResultsIn DCR, 157,551 patients from 374 US practices were prescribed a glucose-lowering medication. Patients with morbid obesity were more likely treated with medications prone to cause weight gain (relative rate [RR] 1.09, 95% CI 1.07-1.11). Older patients were more likely to be treated with medications with increased risk of hypoglycemia (RR 1.04 per 5 years, 95% CI 1.04-1.05). Patients with CKD 4/5 were less likely to be treated with agents with known risk in patients with advanced CKD (RR 0.74, 95% CI 0.71-0.77). Patients with coronary artery disease were no more or less likely to be treated with medications with potential cardiovascular safety issues (RR 0.99, 95% CI 0.96-1.01).ConclusionsWe observed some targeted use of glucose-lowering therapies in certain subgroups but also identified potential opportunities for better personalization of treatment. Data sources such as the DCR can highlight potential areas for improving targeted approaches to pharmacologic therapy in order to optimize selection of patients most likely to benefit (and least likely to be harmed) from treatments.
- Published
- 2018
21. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
- Author
-
Sattar, Naveed, McGuire, Darren K., Pavo, Imre, Weerakkody, Govinda J., Nishiyama, Hiroshi, Wiese, Russell J., and Zoungas, Sophia
- Published
- 2022
- Full Text
- View/download PDF
22. Automated liquid handling robot for rapid lateral flow assay development
- Author
-
Anderson, Caitlin E., Huynh, Toan, Gasperino, David J., Alonzo, Luis F., Cantera, Jason L., Harston, Stephen P., Hsieh, Helen V., Marzan, Rosemichelle, McGuire, Shawn K., Williford, John R., Oncina, Ciela I., Glukhova, Veronika A., Bishop, Joshua D., Cate, David M., Grant, Benjamin D., Nichols, Kevin P., and Weigl, Bernhard H.
- Published
- 2022
- Full Text
- View/download PDF
23. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis
- Author
-
Salah, Husam M., Al’Aref, Subhi J., Khan, Muhammad Shahzeb, Al-Hawwas, Malek, Vallurupalli, Srikanth, Mehta, Jawahar L., Mounsey, J. Paul, Greene, Stephen J., McGuire, Darren K., Lopes, Renato D., and Fudim, Marat
- Published
- 2022
- Full Text
- View/download PDF
24. Field evaluation of the diagnostic performance of EasyScan GO: a digital malaria microscopy device based on machine-learning
- Author
-
Das, Debashish, Vongpromek, Ranitha, Assawariyathipat, Thanawat, Srinamon, Ketsanee, Kennon, Kalynn, Stepniewska, Kasia, Ghose, Aniruddha, Sayeed, Abdullah Abu, Faiz, M. Abul, Netto, Rebeca Linhares Abreu, Siqueira, Andre, Yerbanga, Serge R., Ouédraogo, Jean Bosco, Callery, James J., Peto, Thomas J., Tripura, Rupam, Koukouikila-Koussounda, Felix, Ntoumi, Francine, Ong’echa, John Michael, Ogutu, Bernhards, Ghimire, Prakash, Marfurt, Jutta, Ley, Benedikt, Seck, Amadou, Ndiaye, Magatte, Moodley, Bhavani, Sun, Lisa Ming, Archasuksan, Laypaw, Proux, Stephane, Nsobya, Sam L., Rosenthal, Philip J., Horning, Matthew P., McGuire, Shawn K., Mehanian, Courosh, Burkot, Stephen, Delahunt, Charles B., Bachman, Christine, Price, Ric N., Dondorp, Arjen M., Chappuis, François, Guérin, Philippe J., and Dhorda, Mehul
- Published
- 2022
- Full Text
- View/download PDF
25. Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes
- Author
-
McGuire, Darren K., D’Alessio, David, Nicholls, Stephen J., Nissen, Steven E., Riesmeyer, Jeffrey S., Pavo, Imre, Sethuraman, Shanthi, Heilmann, Cory R., Kaiser, John J., and Weerakkody, Govinda J.
- Published
- 2022
- Full Text
- View/download PDF
26. Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease
- Author
-
Stevens, Susanna R., Segar, Matthew W., Pandey, Ambarish, Lokhnygina, Yuliya, Green, Jennifer B., McGuire, Darren K., Standl, Eberhard, Peterson, Eric D., and Holman, Rury R.
- Published
- 2022
- Full Text
- View/download PDF
27. One-year clinical results of restorations using a novel self-adhesive resin-based bulk-fill restorative
- Author
-
Rathke, Andreas, Pfefferkorn, Frank, McGuire, Michael K., Heard, Rick H., and Seemann, Rainer
- Published
- 2022
- Full Text
- View/download PDF
28. Harvest graft substitute for soft tissue volume augmentation around existing implants: A randomized, controlled and blinded multicenter trial.
- Author
-
Clem, Donald S., McClain, Pamela K., McGuire, Michael K., Richardson, Chris R., Santarelli, Greg A., Schallhorn, Rachel A., Scheyer, E. Todd, Gunsolley, John C., and Morelli, Thiago
- Abstract
Background: Using a single‐blind, randomized, controlled, multicenter, practice‐based clinical trial, a volume‐stable collagen matrix (VCMX) was compared with connective tissue graft (CTG) for soft tissue augmentation around existing dental implants. Methods: Sixty patients (31 VCMX and 31 CTG) were included. The primary outcome was a soft tissue thickness change 3 mm below the gingival margin (GM). Secondary outcomes included clinical measures, such as keratinized tissue widths (KTw), probing pocket depths, and pink esthetic scores, and patient‐reported outcomes (PRO). Results: There were no significant differences between test and control patient demographics or clinical measures throughout the 1‐year study. VCMX "grafts" were by design larger than CTG, and surgery time was less (27% less, p = 0.0005). Three millimeters below the GM (primary endpoint), tissue thickness increase was noninferior for VCMX compared with CTG (0.93 ± 0.80 mm vs. 1.10 ± 0.51 mm, respectively), inferior (by 0.25 mm) at 1 mm, and noninferior at 5 mm. Postoperative pain was significantly less for VCMX patients (p < 0.0001), but all other PRO measures, including esthetics and satisfaction, improved similarly for both therapies. Conclusions: Given the inclusion criteria for this study, namely soft tissue augmentation around existing implants with some evidence of KTw and minimal recession, VCMX provided soft tissue thickness and volume increases similar (noninferior) to CTG. Clinical measures and PRO were similar between therapies—site sensitivity and esthetics improved similarly for both therapies—but surgery time and pain following surgery were significantly less for VCMX. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Sodium-Glucose Cotransporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure.
- Author
-
Duvalyan, Angela, La Hoz, Ricardo M., McGuire, Darren K., and Drazner, Mark H.
- Abstract
• Although sodium-glucose cotransporter-2 inhibitors (SGLT2is) increase the risk of mycotic genital infections (MGIs) and possibly urinary tract infections (UTIs), their cardiovascular benefits in patients with heart failure far outweigh those risks. • Patients receiving SGLT2is should be educated about steps to reduce risks of MGI/UTIs. • For MGI/UTI concerns, few conditions (current or recurrent MGI/UTIs, adult polycystic kidney disease) preclude starting SGLT2is. • If an uncomplicated MGI/UTI occurs, reflexive discontinuation of SGLT2is is not necessary. • If SGLT2is are stopped due to MGI/UTIs, plans to reinitiate them should be made. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) improve clinical outcomes in persons with heart failure (HF). This class of agents has been consistently associated with an increased risk of mycotic genital infections (MGIs), and in some, but not all trials, urinary tract infections (UTIs). Other medications widely used for cardiac conditions do not cause MGIs and UTIs, so cardiologists and their supporting teams will be encountering clinical questions that they previously did not have to address. This review provides clinicians with practical recommendations about SGLT2i use in individuals with HF as related to the associated MGI and possible UTI risks. Overall, given the benefit of SGLT2is in clinical outcomes, the threshold for not initiating or discontinuing SGLT2is due to concerns for MGIs or UTIs should be high for persons with HF. Likewise, when SGLT2is are discontinued for such concerns, the threshold for reinitiation should be low. [Display omitted]. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Correction: Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
- Author
-
McCutcheon, Robert A., Keefe, Richard S. E., and McGuire, Philip K.
- Published
- 2023
- Full Text
- View/download PDF
31. Reinvisioning Coparent Curriculum: Meeting the Needs of a Changing Population
- Author
-
McCann, Ellie, Powell, Sharon, Becher, Emily H., and McGuire, Jenifer K.
- Abstract
The goal of this article is to provide a framework for practitioners to update their curriculum using an in-depth case study of the Parents Forever program. As new research and best practices change, curriculum authors and program administrators should consider revising both the content and method of delivery of their courses. However, little literature exists to document the pragmatics of this process, particularly when operating within the context of a legislative mandate. The case study of the Parents Forever program curriculum update is grounded in a program life cycle model. Using this model, in-depth descriptions are provided, from beginning observations of current classes to final stages of the evaluation. This included piloting, formative evaluation, implementation, and summative evaluation, including results of a year of teaching the new curriculum, which are described along with next steps.
- Published
- 2020
- Full Text
- View/download PDF
32. Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry®
- Author
-
Arnold, Suzanne V, Goyal, Abhinav, Inzucchi, Silvio E, McGuire, Darren K, Tang, Fengming, Mehta, Sanjeev N, Sperling, Laurence S, Maddox, Thomas M, Einhorn, Daniel, Wong, Nathan D, Hammar, Niklas, Fenici, Peter, Khunti, Kamlesh, Lam, Carolyn SP, and Kosiborod, Mikhail
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Diabetes ,Clinical Research ,Cardiovascular ,Prevention ,Health Services ,Metabolic and endocrine ,Good Health and Well Being ,Aged ,Antihypertensive Agents ,Blood Glucose ,Blood Pressure ,Diabetes Complications ,Diabetes Mellitus ,Female ,Healthcare Disparities ,Humans ,Hypertension ,Hypoglycemic Agents ,Male ,Middle Aged ,Practice Patterns ,Physicians' ,Primary Health Care ,Quality Improvement ,Quality Indicators ,Health Care ,Registries ,Treatment Outcome ,United States ,diabetes mellitus ,quality of care ,registry ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
Although guidelines and performance measures exist for patients with diabetes mellitus, achievement of these metrics is not well known. The Diabetes Collaborative Registry® (DCR) was formed to understand the quality of diabetes mellitus care across the primary and specialty care continuum in the United States. We assessed the frequency of achievement of 7 diabetes mellitus-related quality metrics and variability across the Diabetes Collaborative Registry® sites. Among 574 972 patients with diabetes mellitus from 259 US practices, median (interquartile range) achievement of the quality metrics across the practices was the following: (1) glycemic control: 19% (5-47); (2) blood pressure control: 80% (67-88); (3) angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers in patients with coronary artery disease: 62% (51-69); (4) nephropathy screening: 62% (53-71); (5) eye examination: 0.7% (0.0-79); (6) foot examination: 0.0% (0.0-2.3); and (7) tobacco screening/cessation counseling: 86% (80-94). In hierarchical, modified Poisson regression models, there was substantial variability in meeting these metrics across sites, particularly with documentation of glycemic control and eye and foot examinations. There was also notable variation across specialties, with endocrinology practices performing better on glycemic control and diabetes mellitus foot examinations and cardiology practices succeeding more in blood pressure control and use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers. The Diabetes Collaborative Registry® was established to document and improve the quality of outpatient diabetes mellitus care. While target achievement of some metrics of cardiovascular risk modification was high, achievement of others was suboptimal and highly variable. This may be attributable to fragmentation of care, lack of ownership among various specialists concerning certain domains of care, incomplete documentation, true gaps in care, or a combination of these factors.
- Published
- 2017
33. Multimodality Strategy for Cardiovascular Risk Assessment
- Author
-
de Lemos, James A, Ayers, Colby R, Levine, Benjamin D, deFilippi, Christopher R, Wang, Thomas J, Hundley, W Gregory, Berry, Jarett D, Seliger, Stephen L, McGuire, Darren K, Ouyang, Pamela, Drazner, Mark H, Budoff, Matthew, Greenland, Philip, Ballantyne, Christie M, and Khera, Amit
- Subjects
Epidemiology ,Biomedical and Clinical Sciences ,Health Sciences ,Heart Disease - Coronary Heart Disease ,Cardiovascular ,Patient Safety ,Aging ,Prevention ,Heart Disease ,Atherosclerosis ,Clinical Research ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Good Health and Well Being ,Adult ,Aged ,Biomarkers ,Cardiovascular Diseases ,Cohort Studies ,Combined Modality Therapy ,Electrocardiography ,Ethnicity ,Female ,Follow-Up Studies ,Humans ,Male ,Middle Aged ,Population Surveillance ,Prospective Studies ,Risk Assessment ,Texas ,biomarker ,C-reactive protein ,coronary calcium ,NT-proBNP ,risk prediction ,troponin T ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Public Health and Health Services ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences ,Sports science and exercise - Abstract
BackgroundCurrent strategies for cardiovascular disease (CVD) risk assessment among adults without known CVD are limited by suboptimal performance and a narrow focus on only atherosclerotic CVD (ASCVD). We hypothesized that a strategy combining promising biomarkers across multiple different testing modalities would improve global and atherosclerotic CVD risk assessment among individuals without known CVD.MethodsWe included participants from MESA (Multi-Ethnic Study of Atherosclerosis) (n=6621) and the Dallas Heart Study (n=2202) who were free from CVD and underwent measurement of left ventricular hypertrophy by ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein. Associations of test results with the global composite CVD outcome (CVD death, myocardial infarction, stroke, coronary or peripheral revascularization, incident heart failure, or atrial fibrillation) and ASCVD (fatal or nonfatal myocardial infarction or stroke) were assessed over >10 years of follow-up. Multivariable analyses for the primary global CVD end point adjusted for traditional risk factors plus statin use and creatinine (base model).ResultsEach test result was independently associated with global composite CVD events in MESA after adjustment for the components of the base model and the other test results (P
- Published
- 2017
34. What’s normal? Oligosaccharide concentrations and profiles in milk produced by healthy women vary geographically 1 , 2
- Author
-
McGuire, Michelle K, Meehan, Courtney L, McGuire, Mark A, Williams, Janet E, Foster, James, Sellen, Daniel W, Kamau-Mbuthia, Elizabeth W, Kamundia, Egidioh W, Mbugua, Samwel, Moore, Sophie E, Prentice, Andrew M, Kvist, Linda J, Otoo, Gloria E, Brooker, Sarah L, Price, William J, Shafii, Bahman, Placek, Caitlyn, Lackey, Kimberly A, Robertson, Bianca, Manzano, Susana, Ruíz, Lorena, Rodríguez, Juan M, Pareja, Rossina G, and Bode, Lars
- Subjects
Genetics ,Nutrition ,Adult ,Age Factors ,Body Mass Index ,Body Weight ,Breast Feeding ,Cross-Sectional Studies ,Environment ,Ethnicity ,Female ,Gambia ,Gene-Environment Interaction ,Humans ,Lactation ,Milk ,Human ,Oligosaccharides ,Postpartum Period ,Reference Values ,Sweden ,Young Adult ,breastfeeding ,carbohydrates ,human milk ,lactation ,oligosaccharides ,Engineering ,Medical and Health Sciences ,Nutrition & Dietetics - Abstract
Background: Human milk is a complex fluid comprised of myriad substances, with one of the most abundant substances being a group of complex carbohydrates referred to as human milk oligosaccharides (HMOs). There has been some evidence that HMO profiles differ in populations, but few studies have rigorously explored this variability.Objectives: We tested the hypothesis that HMO profiles differ in diverse populations of healthy women. Next, we examined relations between HMO and maternal anthropometric and reproductive indexes and indirectly examined whether differences were likely related to genetic or environmental variations.Design: In this cross-sectional, observational study, milk was collected from a total of 410 healthy, breastfeeding women in 11 international cohorts and analyzed for HMOs by using high-performance liquid chromatography.Results: There was an effect of the cohort (P < 0.05) on concentrations of almost all HMOs. For instance, the mean 3-fucosyllactose concentration was >4 times higher in milk collected in Sweden than in milk collected in rural Gambia (mean ± SEM: 473 ± 55 compared with 103 ± 16 nmol/mL, respectively; P < 0.05), and disialyllacto-N-tetraose (DSLNT) concentrations ranged from 216 ± 14 nmol/mL (in Sweden) to 870 ± 68 nmol/mL (in rural Gambia) (P < 0.05). Maternal age, time postpartum, weight, and body mass index were all correlated with several HMOs, and multiple differences in HMOs [e.g., lacto-N-neotetrose and DSLNT] were shown between ethnically similar (and likely genetically similar) populations who were living in different locations, which suggests that the environment may play a role in regulating the synthesis of HMOs.Conclusions: The results of this study support our hypothesis that normal HMO concentrations and profiles vary geographically, even in healthy women. Targeted genomic analyses are required to determine whether these differences are due at least in part to genetic variation. A careful examination of sociocultural, behavioral, and environmental factors is needed to determine their roles in this regard. This study was registered at clinicaltrials.gov as NCT02670278.
- Published
- 2017
35. Editorial: ARDS: Reaching for the Horizon
- Author
-
McGuire, John K, Schwingshackl, Andreas, and Anand, Kanwaljeet JS
- Subjects
Paediatrics ,Biomedical and Clinical Sciences ,pediatric acute respiratory distress syndrome ,acute lung injury ,pathophysiology ,treatment ,fluid management ,Paediatrics and Reproductive Medicine ,Other Medical and Health Sciences - Published
- 2017
36. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
- Author
-
Apperloo, Ellen M, Neuen, Brendon L, Fletcher, Robert A, Jongs, Niels, Anker, Stefan D, Bhatt, Deepak L, Butler, Javed, Cherney, David Z I, Herrington, William G, Inzucchi, Silvio E, Jardine, Meg J, Liu, Chih-Chin, Mahaffey, Kenneth W, McGuire, Darren K, McMurray, John J V, Neal, Bruce, Packer, Milton, Perkovic, Vlado, Sabatine, Marc S, Solomon, Scott D, Staplin, Natalie, Szarek, Michael, Vaduganathan, Muthiah, Wanner, Christoph, Wheeler, David C, Wiviott, Stephen D, Zannad, Faiez, and Heerspink, Hiddo J L
- Abstract
SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are consistent in patients receiving and not receiving GLP-1 receptor agonists.
- Published
- 2024
- Full Text
- View/download PDF
37. Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes
- Author
-
Segar, Matthew W., Patel, Kershaw V., Vaduganathan, Muthiah, Caughey, Melissa C., Jaeger, Byron C., Basit, Mujeeb, Willett, Duwayne, Butler, Javed, Sengupta, Partho P., Wang, Thomas J., McGuire, Darren K., and Pandey, Ambarish
- Published
- 2021
- Full Text
- View/download PDF
38. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
- Author
-
O’Donoghue, Michelle L., Kato, Eri T., Mosenzon, Ofri, Murphy, Sabina A., Cahn, Avivit, Herrera, Marisol, Tankova, Tsvetalina, Šmahelová, Alena, Merlini, Piera, Gause-Nilsson, Ingrid, Langkilde, Anna Maria, McGuire, Darren K., Wilding, John P. H., Leiter, Larry A., Bhatt, Deepak L., Raz, Itamar, Sabatine, Marc S., and Wiviott, Stephen D.
- Published
- 2021
- Full Text
- View/download PDF
39. Heart Disease and Stroke Statistics—2016 Update
- Author
-
Mozaffarian, Dariush, Benjamin, Emelia J, Go, Alan S, Arnett, Donna K, Blaha, Michael J, Cushman, Mary, Das, Sandeep R, de Ferranti, Sarah, Després, Jean-Pierre, Fullerton, Heather J, Howard, Virginia J, Huffman, Mark D, Isasi, Carmen R, Jiménez, Monik C, Judd, Suzanne E, Kissela, Brett M, Lichtman, Judith H, Lisabeth, Lynda D, Liu, Simin, Mackey, Rachel H, Magid, David J, McGuire, Darren K, Mohler, Emile R, Moy, Claudia S, Muntner, Paul, Mussolino, Michael E, Nasir, Khurram, Neumar, Robert W, Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K, Reeves, Mathew J, Rodriguez, Carlos J, Rosamond, Wayne, Sorlie, Paul D, Stein, Joel, Towfighi, Amytis, Turan, Tanya N, Virani, Salim S, Woo, Daniel, Yeh, Robert W, and Turner, Melanie B
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Health Sciences ,Clinical Sciences ,Sports Science and Exercise ,American Heart Association ,Data Interpretation ,Statistical ,Heart Diseases ,Humans ,Life Style ,Research Report ,Stroke ,United States ,AHA Scientific Statements ,cardiovascular diseases ,epidemiology ,risk factors ,statistics ,stroke ,Writing Group Members ,American Heart Association Statistics Committee ,Stroke Statistics Subcommittee ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences ,Sports science and exercise - Published
- 2016
40. Executive Summary
- Author
-
Mozaffarian, Dariush, Benjamin, Emelia J, Go, Alan S, Arnett, Donna K, Blaha, Michael J, Cushman, Mary, Das, Sandeep R, de Ferranti, Sarah, Després, Jean-Pierre, Fullerton, Heather J, Howard, Virginia J, Huffman, Mark D, Isasi, Carmen R, Jiménez, Monik C, Judd, Suzanne E, Kissela, Brett M, Lichtman, Judith H, Lisabeth, Lynda D, Liu, Simin, Mackey, Rachel H, Magid, David J, McGuire, Darren K, Mohler, Emile R, Moy, Claudia S, Muntner, Paul, Mussolino, Michael E, Nasir, Khurram, Neumar, Robert W, Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K, Reeves, Mathew J, Rodriguez, Carlos J, Rosamond, Wayne, Sorlie, Paul D, Stein, Joel, Towfighi, Amytis, Turan, Tanya N, Virani, Salim S, Woo, Daniel, Yeh, Robert W, and Turner, Melanie B
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Health Sciences ,Clinical Sciences ,Sports Science and Exercise ,American Heart Association ,Data Interpretation ,Statistical ,Health Behavior ,Heart Diseases ,Humans ,Research Report ,Stroke ,United States ,AHA Scientific Statements ,cardiovascular diseases ,epidemiology ,risk factors ,statistics ,stroke ,Writing Group Members ,American Heart Association Statistics Committee ,Stroke Statistics Subcommittee ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences ,Sports science and exercise - Published
- 2016
41. Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association.
- Author
-
Writing Group Members, Mozaffarian, Dariush, Benjamin, Emelia J, Go, Alan S, Arnett, Donna K, Blaha, Michael J, Cushman, Mary, Das, Sandeep R, de Ferranti, Sarah, Després, Jean-Pierre, Fullerton, Heather J, Howard, Virginia J, Huffman, Mark D, Isasi, Carmen R, Jiménez, Monik C, Judd, Suzanne E, Kissela, Brett M, Lichtman, Judith H, Lisabeth, Lynda D, Liu, Simin, Mackey, Rachel H, Magid, David J, McGuire, Darren K, Mohler, Emile R, Moy, Claudia S, Muntner, Paul, Mussolino, Michael E, Nasir, Khurram, Neumar, Robert W, Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K, Reeves, Mathew J, Rodriguez, Carlos J, Rosamond, Wayne, Sorlie, Paul D, Stein, Joel, Towfighi, Amytis, Turan, Tanya N, Virani, Salim S, Woo, Daniel, Yeh, Robert W, Turner, Melanie B, American Heart Association Statistics Committee, and Stroke Statistics Subcommittee
- Subjects
Writing Group Members ,American Heart Association Statistics Committee ,Stroke Statistics Subcommittee ,Humans ,Heart Diseases ,Data Interpretation ,Statistical ,Health Behavior ,American Heart Association ,United States ,Stroke ,Research Report ,AHA Scientific Statements ,cardiovascular diseases ,epidemiology ,risk factors ,statistics ,stroke ,Data Interpretation ,Statistical ,Clinical Sciences ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology - Published
- 2016
42. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.
- Author
-
Writing Group Members, Mozaffarian, Dariush, Benjamin, Emelia J, Go, Alan S, Arnett, Donna K, Blaha, Michael J, Cushman, Mary, Das, Sandeep R, de Ferranti, Sarah, Després, Jean-Pierre, Fullerton, Heather J, Howard, Virginia J, Huffman, Mark D, Isasi, Carmen R, Jiménez, Monik C, Judd, Suzanne E, Kissela, Brett M, Lichtman, Judith H, Lisabeth, Lynda D, Liu, Simin, Mackey, Rachel H, Magid, David J, McGuire, Darren K, Mohler, Emile R, Moy, Claudia S, Muntner, Paul, Mussolino, Michael E, Nasir, Khurram, Neumar, Robert W, Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K, Reeves, Mathew J, Rodriguez, Carlos J, Rosamond, Wayne, Sorlie, Paul D, Stein, Joel, Towfighi, Amytis, Turan, Tanya N, Virani, Salim S, Woo, Daniel, Yeh, Robert W, Turner, Melanie B, American Heart Association Statistics Committee, and Stroke Statistics Subcommittee
- Subjects
Writing Group Members ,American Heart Association Statistics Committee ,Stroke Statistics Subcommittee ,Humans ,Heart Diseases ,Data Interpretation ,Statistical ,Life Style ,American Heart Association ,United States ,Stroke ,Research Report ,AHA Scientific Statements ,cardiovascular diseases ,epidemiology ,risk factors ,statistics ,stroke ,Data Interpretation ,Statistical ,Clinical Sciences ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology - Published
- 2016
43. Manganese oxide nanosheets and a 2D hybrid of graphene-manganese oxide nanosheets synthesized by liquid-phase exfoliation
- Author
-
Coelho, Joao, Mendoza-Sanchez, Beatriz, Pettersson, Henrik, Pokle, Anuj, McGuire, Eva K., Long, Edmund, McKeon, Lorcan, Bell, Alan P., and Nicolosi, Valeria
- Subjects
Condensed Matter - Materials Science - Abstract
Manganese oxide nanosheets were synthesized using liquid phase exfoliation that achieved suspensions in isopropanol with concentrations of up to 0.45 mg/ml. A study of solubility parameters showed that the exfoliation was optimum in DMF followed by isopropanol and diethylene glycol. Isopropanol was the solvent of choice due to its environmentally friendly nature and ease of use for further processing. The 2D hybrid was synthesized in isopropanol suspensions with concentrations of up to 0.5 mg/ml and demonstrated stability against reaggregation for up to six months. The coexfoliation was found to be an energetically favorable process in which both solutes, graphene and manganese oxide nanosheets, exfoliate with an improved yield as compared to the single solute exfoliation procedure. This work demonstrates the remarkable versatility of liquid phase exfoliation with respect to the synthesis of hybrids with tailored properties, and it provides proof of concept ground work for further future investigation and exploitation of hybrids made of two or more 2D nanomaterials that have key complementary properties for various technological applications.
- Published
- 2014
44. Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension Analysis From the Dallas Heart Study
- Author
-
Tientcheu, Danielle, Ayers, Colby, Das, Sandeep R, McGuire, Darren K, de Lemos, James A, Khera, Amit, Kaplan, Norman, Victor, Ronald, and Vongpatanasin, Wanpen
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Hypertension ,Clinical Research ,Cardiovascular ,Heart Disease ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Antihypertensive Agents ,Blood Pressure ,Blood Pressure Determination ,Cohort Studies ,Ethnicity ,Female ,Follow-Up Studies ,Humans ,Male ,Masked Hypertension ,Middle Aged ,Outcome Assessment ,Health Care ,Prevalence ,Prognosis ,Risk Factors ,Texas ,White Coat Hypertension ,Young Adult ,African Americans ,arterial stiffness ,blood pressure ,multiethnic ,outcome assessment ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
BackgroundMultiple epidemiological studies from Europe and Asia have demonstrated increased cardiovascular risks associated with isolated elevation of home blood pressure (BP) or masked hypertension (MH). Previous studies have not addressed cardiovascular outcomes associated with MH and white-coat hypertension (WCH) in the general population in the United States.ObjectivesThe goal of this study was to determine hypertensive target organ damage and adverse cardiovascular outcomes associated with WCH (high clinic BP, ≥140/90 mm Hg; normal home BP,
- Published
- 2015
45. Gender-Related Disparities in Sport, Physical Activity, and Physical Activity Lessons in Minnesota From 2016 to 2019.
- Author
-
Kaja, Sarah M. and McGuire, Jenifer K.
- Abstract
To leverage multi-year panel data to determine statewide trends of participation in team sports, physical activity (PA) lessons, and overall PA among transgender and gender diverse (TGD) adolescents in 2016 and 2019. Frequencies and percentages for TGD adolescents' team sport and PA lesson involvement, as well as mean number of days of ≥ 60 minutes of PA in the previous week, were compared in 2016 and 2019 to cisgender youth. In both years, cisgender students were about twice as likely to participate in sports and engaged in an average of one additional full day per week of PA for ≥ 60 minutes. Students unsure of their gender identity participated slightly more than those identifying as transgender, genderqueer, genderfluid, or nonbinary. We extend previous literature by demonstrating how gender-related participation gaps existed for Minnesotan high school students in 2016 and persisted into 2019, and we added distinctions for identities within the TGD umbrella (e.g., unsure). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
- Author
-
McGuire, Darren K., Inzucchi, Silvio E., Johansen, Odd Erik, Rosenstock, Julio, George, Jyothis T., and Marx, Nikolaus
- Published
- 2021
- Full Text
- View/download PDF
47. Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes
- Author
-
Berg, David D., Kolkailah, Ahmed A., Sarraju, Ashish, Kerchberger, Anne Marie, Eljalby, Mahmoud, and McGuire, Darren K.
- Published
- 2021
- Full Text
- View/download PDF
48. Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study
- Author
-
Howes, Oliver D., Bonoldi, Ilaria, McCutcheon, Robert A., Azis, Matilda, Antoniades, Mathilde, Bossong, Matthijs, Modinos, Gemma, Perez, Jesus, Stone, James M., Santangelo, Barbara, Veronese, Mattia, Grace, Anthony, Allen, Paul, and McGuire, Philip K.
- Published
- 2020
- Full Text
- View/download PDF
49. Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11)
- Author
-
Amod, Aslam, Buse, John B., McGuire, Darren K., Pieber, Thomas R., Pop-Busui, Rodica, Pratley, Richard E., Zinman, Bernard, Hansen, Marco Bo, Jia, Ting, Mark, Thomas, and Poulter, Neil R.
- Published
- 2020
- Full Text
- View/download PDF
50. Executive Summary
- Author
-
Mozaffarian, Dariush, Benjamin, Emelia J, Go, Alan S, Arnett, Donna K, Blaha, Michael J, Cushman, Mary, de Ferranti, Sarah, Després, Jean-Pierre, Fullerton, Heather J, Howard, Virginia J, Huffman, Mark D, Judd, Suzanne E, Kissela, Brett M, Lackland, Daniel T, Lichtman, Judith H, Lisabeth, Lynda D, Liu, Simin, Mackey, Rachel H, Matchar, David B, McGuire, Darren K, Mohler, Emile R, Moy, Claudia S, Muntner, Paul, Mussolino, Michael E, Nasir, Khurram, Neumar, Robert W, Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K, Reeves, Mathew J, Rodriguez, Carlos J, Sorlie, Paul D, Stein, Joel, Towfighi, Amytis, Turan, Tanya N, Virani, Salim S, Willey, Joshua Z, Woo, Daniel, Yeh, Robert W, and Turner, Melanie B
- Subjects
Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Public Health and Health Services ,Cardiovascular System & Hematology - Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.